Head of Investor Relations Welcome to the Q4 and full year 2024 conference call for investors and analysts. As usual, you can find the slides on sanofi.com. Please turn to Slide 3. Here we have the ...

Sanofi’s jump in earnings comes with an increased emphasis on R&D and vaccines, plus an eye cast toward M&A to shore up its pipeline.

Teva Pharmaceutical Industries TEVA reported fourth-quarter 2024 adjusted earnings of 71 cents per share, which beat the ...

When Takeda CEO Christophe Weber retires from the company in June 2026, a familiar face among the Massachusetts biotech scene will take over leading the Japanese pharma giant.

Chief R&D and commercial officer Najat Khan, PhD, tells GEN Edge company aims to improve design of studies, accelerate enrollment, and enhance evidence generation.

Dry Skin Cream, Lotion, and Ointment MarketThe global dry skin cream, lotion, and ointment market is on the cusp of substantial expansion, according to recent market analysis. The industry is ...

Shionogi’s oral antiviral for respiratory syncytial virus (RSV) has met its primary endpoint in a Phase II study that saw ...

Any NYT reader looking at the buzzy front page headline below would immediately think that Robert F. Kennedy Jr. is a madman. Can he really be an advocate for repealing the polio vaccine, a disease ...

While Sanofi’s immunology megablockbuster Dupixent predictably dominated the company’s sales charts in 2024, a new golden ...

Sanofi’s Sarclisa (isatuximab) has been approved by the Medicines and Healthcare product Regulatory Agency (MHRA) as part of a combination treatment for newly diagnosed multiple myeloma (MM).

Montelukast does not appear to increase the risk for neuropsychiatric adverse events in children and adolescents, according to a study published in JAMA Pediatrics. Montelukast is a leukotriene ...

US pharma giant Merck & Co today revealed an early stop to the Phase III HYPERION study evaluating Winrevair (sotatercept-csrk) versus placebo (both in combination with background therapy) in recently ...